Saturday, February 8, 2020
Program is subject to change

7:00 am	Registration and Continental Breakfast
7:50	Welcome and Overview / Pre-Program Test Philip J. Rosenfeld, MD, PhD, Harry W. Flynn, Jr., MD, and Thomas A. Albini, MD
	Session I: Aging, Disease Pathogenesis, and Imaging Moderators: Philip J. Rosenfeld, MD, PhD and Zohar Yehoshua, MD, MHA
8:00	Metabolic Networks and the RPE-Photoreceptor Ecosystem in Aging and Degeneration Philip Luthert, MBBS
8:08	Deep Learning and Reticular Pseudodrusen Emily Y. Chew, MD
8:16	Ultrahigh Speed OCTA for Assessing Choricapillaris Flow Impairment James G. Fujimoto, PhD
8:24	Challenges in Imaging the Choriocapillaris Richard F. Spaide, MD
8:32	Choriocapillaris Quantification with Phansalkar's Local Thresholding: Do's and Don'ts Zhongdi Chu, PhD
8:40	Swept Source OCTA Imaging of Choriocapillaris Associated with Drusen in AMD Philip J. Rosenfeld, MD, PhD
8:48	Choriocapillaris in Intermediate AMD Robyn Guymer, MBBS, PhD, FRANZCO
8:56	Do Choriocapillaris Flow Deficits Correlate with the Rate and Directionality of GA Growth? Eric M. Moult, BSc
9:04	Choriocapillaris in Myopia SriniVas R. Sadda, MD
9:12	Choroidal Vessel Imaging and Quantification Ruikang (Ricky) Wang, PhD
9:20	Structural OCT Imaging to Differentiate Between PIC, PIC-CNV and Myopic-CNV Xiaoxin Li, MD
	Session II: Retinal Diseases and Functional Endpoints Moderators: Thomas A. Albini, MD and Jorge A. Fortun, MD
9:28	Retina Trends – A VC’s Perspective Emmett T. Cunningham, Jr., MD, PhD, MPH
9:36	MacTel2 as a “Serine/Ceramide-Opathy” Martin Friedlander, MD, PhD
9:44	Epidemiology of Common Retinal Diseases in Retina Practices in the United States Andrew A. Moshfeghi, MD, MBA
9:52	Functional Imaging of Mitochondria in Retinal Diseases Rishi P. Singh, MD
10:00	Novel Analytics to Examine Impact of Fluctuations in Retinal Thickness on Visual Outcomes Usha Chakravarthy, MD
10:08	Integrating Microperimetry into Clinical Trials of Nonexudative AMD Nadia Waheed, MD
10:16	Rod-and-Cone-Mediated Vision in Eyes with Hyperreflective Foci: An Outcome Measure for Oil Spill Trials? Christine A. Curcio, PhD
10:24	Normal and Low Luminance Quantitative Contrast Sensitivity: A Novel Functional Endpoint for Rapid Measurement of Spatial Contrast Sensitivity Functions in Dry AMD Karl G. Csaky, MD, PhD
	Session III: AMD I Moderators: Philip J. Rosenfeld, MD, PhD and Raquel Goldhardt, MD
10:32	Update on Gene Therapy for Complement Inhibition Jay S. Duker, MD
10:40	Kamuvudines for AMD: The Saga Continues Jayakrishna Ambati, MD
10:48	Phase 1 Results of a Systemic Antisense Inhibitor of Complement Factor B for Geographic Atrophy Sunil S. Patel, MD, PhD
10:56	Phase 1 Single and Multiple Dose Safety Study of Anti-High Temperature Requirement A1 (HtrA1) in Geographic Atrophy (GA) Vrinda Hershberger, MD, PhD
11:04	Update on Elamipretide for the Treatment of AMD Scott W. Cousins, MD
11:12	Three-Part Talk on Anti-Integrin Therapy with Risuteganib in Dry AMD 1-Pre-Clinical Data Glenn J. Jaffe, MD
	2-Phase 2 Study Results Peter K. Kaiser, MD
	3-Structure/Function Correlations Glenn J. Jaffe, MD
11:28	Update on Brimonidine Intravitreal Implant for Dry AMD Ryan Rich, MD
11:36	Avacincaptad Pegol, a Novel C5 Inhibitor for the Treatment of Geographic Atrophy Karl G. Csaky, MD, PhD
11:44	Pegcetacoplan, a Novel C3 Inhibitor for the Treatment of Geographic Atrophy Cedric G. Francois, MD, PhD
	Session IV: AMD II Moderators: Harry W. Flynn, Jr., MD and Luis J. Haddock, MD
11:52	PROCON Year 2 Results Jeffrey S. Heier, MD
12:00pm	Non-Neovascular Exudative Age Related Macular Degeneration: How to Unmask the Masquerader David Sarraf, MD
12:08	Update on Stem Cell Therapies for AMD Amir H. Kashani, MD, PhD
12:16	Retinal Implants: Where Are We Now? Jean-François Korobelnik, MD
12:24	Advanced Retinal Implants Mark S. Humayun, MD, PhD
12:32	Lunch
	Session V: Macular Neovasculation in AMD Moderators: Philip J. Rosenfeld, MD, PhD and Stephan Michels, MD, MBA
1:00	The Importance of MNV Type Classification in the Interpretation of the Results of Clinical Trials Giovanni Staurenghi, MD
1:08	Detection of Non-Exudative Subclinical MNV in AMD from Structural OCT Scans Using Deep Learning Aaron Y. Lee, MD
1:16	AI Based Fluid Quantification on Serial OCT Images from a Patient Self-operated Home OCT Device Anat Loewenstein, MD
1:24	Automated Volumetric Assessment of Subclinical Non-Exudative MNV Using SS-OCTA Luis de Sisternes, PhD
1:32	Rotational 3D OCTA Giuseppe Querques, MD, PhD
	Session VI: Polypoidal Choroidal Vasculopathy Moderators: Philip J. Rosenfeld, MD, PhD and Jackie Kovach, MD
1:40	Diagnosis of PCV Using SS-OCTA Hiroko Terasaki, MD, PhD
1:48	Volume Rendering of OCTA in PCV K. Bailey Freund, MD
1:56	A Comparison Study of Polypoidal Choroidal Vasculopathy Imaged with ICGA and SS-OCTA Seung-Young Yu, MD
2:04	Longitudinal Changes in Subclinical PCV Gemmy Cheung, MBBS, FRCOphth, FAMS, MCI
	Session VII: Treatments for Neovasculation in AMD and ROP Moderators: Thomas A. Albini, MD and Ninel Z. Gregori, MD
2:12	Immunology of Gene Therapy Janet L. Davis, MD
2:20	Phase 1 Study of Intravitreal Gene Therapy with ADVM-022 for Neovascular AMD (OPTIC Trial) David S. Boyer, MD
2:28	RGX-314 Gene Therapy for wAMD and Diabetic Retinopathy Jeffrey S. Heier, MD
2:36	Treatment of Newly Diagnosed and Treatment Resistant Neovascular AMD with the Oral CCR3 Inhibitor ALK4290 Michael W. Stewart, MD
2:44	Results of the Phase I/II SUSHI Study of Intravitreal RBM-007 in Exudative AMD Quan Dong Nguyen, MD, MSc
2:52	Update on Phase 1b and Phase 2 Studies of KSI-301: A Novel Anti-VEGF Antibody Biopolymer Conjugate with Potential for Extended Durability in Wet AMD Diana V. Do, MD
3:00	Results of the Opthea OPT-302 Phase 2b Study: Combined VEGF-C / VEGF-D Suppression for nvAMD Pravin U. Dugel, MD
3:08	Phase 2 LADDER Trial Using the Port Delivery System with Ranibizumab: End of Study, Long-term Follow-up Results Carl D. Regillo, MD
3:16	Faricimab Update Karl G. Csaky, MD, PhD
3:24	Update on the Safety and Efficacy of Abicipar Pegol Baruch D. Kuppermann, MD, PhD
3:32	Brolucizumab Update Lawrence J. Singerman, MD
3:40	Do We Need More VEGF Blockade?- The Rationale for a Clinical Trial Testing High-Dose Aflibercept David M. Brown, MD
3:48	Update on ROP and Anti-VEGF Clinical Trials Darius M. Moshfeghi, MD
	Session VIII: Diabetes Moderators: Harry W. Flynn, Jr. MD and Justin H. Townsend, MD
3:56	Effect of Industry Funding on Abstract Bias in the Literature for Intravitreal Pharmacotherapy for Retinal Vascular Disease Jayanth Sridhar, MD
4:04	DRCR Retina Network Trials and Real World Experience Jennifer Sun, MD
4:12	Diabetic Retinopathy Severity Score: Friend or Foe? Lee M. Jampol, MD
4:20	AI-Assisted Approaches for Diabetic Retinopathy Screening Michael S. Ip, MD
4:28	The Pattern and Density of Retinal Capillary Plexuses from the Fovea to the Periphery Using SS-OCTA Ramin Tadayoni, MD, PhD
4:36	Wide-field SS-OCTA is Better than FA in Detecting Capillary Dropout, Neovascularization and IRMA in Diabetic Retinopathy Toshinori Murata, MD, PhD
4:44	Wide-field SS-OCTA in Diabetic Retinopathy Harry W. Flynn, Jr. MD
4:52	Development of DME in Fellow Eyes from VIVID/VISTA Dilsher Dhoot, MD
5:00	Intravitreal Aflibercept for Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy (NPDR): 2-Year Outcomes of the Phase 3 PANORAMA Study Charles C. Wykoff, MD, PhD
	Session IX: Diabetes, Uveitis, and Retinal Degenerations Moderator: Philip J. Rosenfeld, MD, PhD and Thomas A. Albini, MD
5:08	Results of a Phase 1 Study Using the Integrin Antagonist THR-687 in Patients with DME Arshad Khanani, MD
5:16	A Phase 2 Study of OCS-01: An Effective Topical Dexamethasone for DME Pravin U. Dugel, MD
5:24	Front-line Local Therapies for Uveitis: From Clinical Trials to Practice Steven Yeh, MD
5:32	Update on Therapeutic Superchoroidal Injection Thomas A. Albini, MD
5:40	The Expanding Clinical Spectrum of S-Cone Enhanced Disease or NR2E3 Lawrence A. Yannuzzi, MD
5:48	Treatments and Clinical Trials in Inherited Retinal Degenerations Byron L. Lam, MD
5:56	Results of a Clinical Trial Investigating N-acetylcysteine in Retinitis Pigmentosa Peter A. Campochiaro, MD
6:04	Post-Program Test and Closing Remarks
6:10	Adjourn/Cocktail Reception